


04 ASIAN CANCERS

**Cancer Epigenetics** 



Team

## Team members Lili Li, Lijun Peng, Jianlian Xie, Chu Wu, Xiaoxue Chai, Jun Zhou, Andrew Chen, Johnson Liu

# **Research Progress Summary**

Qian Tao and his research team work on the epigenomic alterations of cancers and identify novel TSGs epigenetically inactivated. The team studies the epigenetic disruption of cell signalling regulation via silencing signalling TSGs by promoter CpG methylation in tumourigenesis. One important aspect is Epstein-Bar virus (EBV)induced aberrant epigenetic programming in EBV-associated tumours including NPC. Despite the findings from extensive whole-genome sequencing studies, CpG methylation-related gene silencing remains the most common genetic alteration detected in NPC, while epigenomic studies have led to the identification of a series of cancer genes frequently methylated in NPC. These genes include regulators of cell signalling and epigenetic modifiers, supporting that viralinduced epigenetic abnormalities have a key role in NPC pathogenesis.



The team previously identified a novel disrupted gene ZDHHC1 epigenetically functioning as a tumour suppressor in multiple malignancies. They further found that ZDHHC1 protein is an S-palmitoyltransferase and p53 as a substrate for ZDHHC1-mediated palmitoylation. This novel form of posttranslational modification of p53 is required for its nuclear translocation. Thus, the epigenetic feedback loop formed by ZDHHC1 and p53 sheds light on the inactivation of p53 without genetic mutations. In another study, they identified ZBTB28 as a tumour suppressor gene by inducing autophagy-related apoptosis in cervical cancer. ZBTB28 promoter methylation could be a biomarker for cervical cancer screening. Meanwhile, the team also identified the epigenetic disruption of TSG promoter methylation as potential epigenetic biomarkers for cancer diagnosis, including TET1 methylation which got a US patent recently.

# **Research and Scholarship**

### **Academic Editorship**

Member's Name	Details			
	Role	Journal		
	Vice-President	The Epigenetics Society		
		Clinical Epigenetics		
		Epigenomes		
	Editorial Board Member	PLoS One		
		Cancer Communications		
		Epigenetic Diagnosis & Therapy		
		Microorganisms		
Qian Tao		Journal of Clinical Epigenetics		
	Panel member and Reviewer	China State Natural Science Award (Ministry of Science and Technology)		
		National Natural Science Foundation of China		
		Worldwide Cancer Research, USA (American Institute for Cancer Research)		
		Singapore Academic Research Council, Ministry of Education, Singapore		
		Foundation for Polish Science, Poland		
	Reviewer	Multi-Year Research Grant, University of Macau, Macau		
		Health and Medical Research Fund, Food and Health Bureau, Hong Kong		
		Children's Cancer and Leukaemia Group, UK		
		Tencent XPLORER Prize		
		Guangdong Science and Technology Departmen		
		Faculty Promotion Committee of Cancer Hospit State Key Laboratory of Oncology in South China, Sun Yat-sen University, Guangdong, China		
	Advisor Committee	Science and Technology Advisor Committee for Shenzhen		
		Basic Research in Shenzhen		
	Academic Advisor	State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Hospital, Guangdong, China		
		Key Laboratory of Biotherapy of Zhejiang Province, Zhejiang University, China		
		Key Laboratory of Ministry of Education, Cancer Research Institute, Central South University, Hunan, China		

Member's Name		
member s Name	Role	
	Overseas Board Member	
Qian Tao	Visiting Chair Professor	

### **Reviewer of Journal / Conference**



### **Grants and Consultancy**

Name	Project Title	Funding Source	Start Date (dd/mm/yyyy)	End Date (dd/mm/yyyy)	Amount (HK\$)
Qian Tao	Regulation of Tumor Cell Invasion/ Metastasis and EMT/ Stemness by a New Ras Antagonist which is Silenced by CpG Methylation in Esophageal Cancer	Research Grants Council – General Research Fund	01/01/2019	30/06/2021	929,280
	Mechanism of Inflammasome Activation by SARS-CoV-2	Research Grants Council – Collaborative Research Fund	01/06/2021	31/05/2024	8,431,247

#### Details

#### Journal

Oncology Section/China Association of Pathophysiology

National Research Center for Urologic Oncology of China/Beijing, Peking University 1<sup>st</sup> Hospital & Institute of Urology, Beijing, China

State Key Laboratory of Oncology in South China, The Cancer Institute, Sun Yat-sen University and SYSU Affiliated Zhongshan Hospital, Guangdong, China

Hunan Yale (XiangYa) School of Medicine, Central South University, Changsha, China

Details				
Journal / Conference				
Nature Communications				
Blood				
Cancer Research				
Lancet				
Cell Death & Differentiation				
The Journal of Pathology				
Oncogene				
Nucleic Acids Research				
Epigenetics				
Clinical Epigenetics				
Advanced Science				
6 <sup>th</sup> Conference of Epigenetics and Biomedicine, Shenzhen, China				


### **Publications**

### A. Journal Papers

- Tang J, Peng W, Feng Y, Le X, Wang K, Xiang Q, Li L, Wang Y, Xu C, Mu J, Xu K, Ji P, Tao Q, Huang A, Deng CX, Lin Y, Xiang T. Cancer cells escape p53's tumor suppression through ablation of ZDHHC1-mediated p53 palmitoylation. *Oncogene*. 2021;40(35):5416-5426. doi:10.1038/ s41388-021-01949-5.
- Li L, Gong Y, Xu K, Chen W, Xia J, Cheng Z, Li L, Yu R, Mu J, Le X, Xiang Q, Peng W, Tang J, Xiang T. ZBTB28 induces autophagy by regulation of FIP200 and Bcl-XL facilitating cervical cancer cell apoptosis. *Journal of Experimental and Clinical Cancer Research*. 2021;40(1). doi:10.1186/s13046-021-01948-0.

### B. Patents

1. Tao Q, Li L. Tumor Suppressor TET1 and Uses Thereof. United States of America, US20190167708.



The epigenetic regulatory loop formed by ZDHHC1, p53, and DNMT3A.

Source: Qian Tao

